Roger Perl­mut­ter lines up deals, fresh fund­ing at Eikon; Sec­ond RSV vac­cine ap­proved; Sev­er­al biotechs flash­ing red; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

As you come back to our web­site this week­end for AS­CO news, don’t for­get to check out our up­dat­ed event line­up at BIO, which will cov­er every­thing from the cur­rent state of VC in­vest­ing in biotech to top phar­ma R&D chiefs dis­cussing how to make pipeline de­ci­sions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.